Three out of four medical directors now say their duties are tied to patient-satisfaction and care-quality metrics

According to the Medical Group Management Association (MGMA) Medical Directorship Compensation Survey, last year, more than 75 percent of the 1,621 medical directors that participated in the survey said their duties were specifically tied to patient-satisfaction and quality-of-care numbers. In addition, more than 35 percent reported that their duties were tied to patient safety metrics.

“Physician practices and other healthcare organizations are dedicated to providing patients the best quality of care,” said Susan L. Turney, MD, MS, FACP, FACMPE, MGMA president and chief executive officer of the Englewood, Colorado-based MGMA in a press release. “Incorporating quality metrics into medical directors’ duties and compensation underscores practices’ commitment to serving their communities.”

Other quality metrics that medical directors also said applied to their duties and compensation included Centers for Medicare and Medicaid Services (CMS) core measures, regulatory compliance, patient readmission rates, and staff and physician satisfaction.

The 1,621 medical directors came from 227 different medical organizations. The full report is for sale on the MGMA website.

Lena Kauffman,

Contributor

Lena Kauffman is a contributing writer based in Ann Arbor, Michigan.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.